A Phase Ib dose confirmation study to establish the minimum effective dose of tolimidone in patients with T1D
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Tolimidone (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 04 Dec 2023 New trial record
- 27 Nov 2023 According to a Biodexa Pharmaceuticals media release, the company plans to conduct this study in conjunction with the Alberta Diabetes Institute at the University of Alberta.